UK Huntingtons Disease Treatment Market Size & Outlook
Related Markets
UK huntingtons disease treatment market highlights
- The UK huntingtons disease treatment market generated a revenue of USD 28.7 million in 2024 and is expected to reach USD 118.1 million by 2030.
- The UK market is expected to grow at a CAGR of 26.1% from 2025 to 2030.
- In terms of segment, symptomatic treatment was the largest revenue generating treatment in 2024.
- Symptomatic Treatment is the most lucrative treatment segment registering the fastest growth during the forecast period.
Huntingtons disease treatment market data book summary
| Market revenue in 2024 | USD 28.7 million |
| Market revenue in 2030 | USD 118.1 million |
| Growth rate | 26.1% (CAGR from 2025 to 2030) |
| Largest segment | Symptomatic treatment |
| Fastest growing segment | Symptomatic Treatment |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Symptomatic Treatment |
| Key market players worldwide | H. Lundbeck AS Class A, Teva Pharmaceutical Industries Ltd, Bausch Health Companies Inc, Hetero, Lupin, Hikma Pharmaceuticals PLC, Dr Reddy's Laboratories Ltd ADR, Sun Pharmaceutical Industries |
Other key industry trends
- In terms of revenue, UK accounted for 5.7% of the global huntingtons disease treatment market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, UK huntingtons disease treatment market is projected to lead the regional market in terms of revenue in 2030.
- UK is the fastest growing regional market in Europe and is projected to reach USD 118.1 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Huntingtons Disease Treatment Market Scope
Huntingtons Disease Treatment Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
UK huntingtons disease treatment market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to huntingtons disease treatment market will help companies and investors design strategic landscapes.
Symptomatic treatment was the largest segment with a revenue share of 128.92% in 2024. Horizon Databook has segmented the UK huntingtons disease treatment market based on symptomatic treatment covering the revenue growth of each sub-segment from 2018 to 2030.
High disease burden coupled with government initiatives and research funding for development of disease treatment may drive market growth in the country. According to Huntington’s Disease Association report 2019, there were around 8,000 patients suffering from HD and 32,000 people were at-risk in the UK. Offspring of patients have a 50% risk of developing the disease.
Clinical trials organized for evaluating drug efficacy and subsequent approval for these drugs are expected to contribute to market growth. In April 2021, University of Aberdeen and 10 other sites in the region are participating in the phase 3 clinical trial of Prilenia Therapeutics B.V.’s candidate- pridopidine for HD.
Reasons to subscribe to UK huntingtons disease treatment market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of UK huntingtons disease treatment market databook
-
Our clientele includes a mix of huntingtons disease treatment market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the UK huntingtons disease treatment market , including forecasts for subscribers. This country databook contains high-level insights into UK huntingtons disease treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
UK huntingtons disease treatment market size, by treatment, 2018-2030 (US$M)
UK Huntingtons Disease Treatment Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
